Zosano Pharma (ZSAN) Completes Enrollment in Zotrip Trial

November 8, 2016 8:43 AM EST
Get Alerts ZSAN Hot Sheet
Trade ZSAN Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Zosano Pharma Corporation (Nasdaq: ZSAN) announced completion of enrollment in its registration-enabling, pivotal efficacy trial (the Zotrip trial), of M207 for the treatment of acute migraine.

“The completion of enrollment in the Zotrip study is a major milestone for the Company and bolsters our confidence in the previously announced availability of trial data in the first quarter of 2017,” commented Konstantinos Alataris, PhD, President and Chief Executive Officer of Zosano Pharma. “The enrollment pace is also indicative of the urgent need for improved treatment options for those suffering with acute migraine.”

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA

Add Your Comment